The phenomenon of pseudoprogression (PsP) on standard imaging can make response assessment difficult in patients with glioblastoma who have undergone standard chemoradiation treatment (CRT). PsP mimics tumor progression on standard imaging, yet is thought to represent a positive biological response to treatment. Recent efforts to define rCBV thresholds to distinguish tumor from treatment effect has enabled the creation of fractional tumor burden (FTB) maps. FTB maps quantify the percent of tumor within an enhancing lesion. This study shows that, within 4-months post-CRT, FTB is a better indicator of PFS and OS than median rCBV or methylation status alone.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords